CHICAGO, IL—Use of an investigational endothelin receptor antagonist in patients with resistant hypertension has a significant impact on both automated office and 24-ambulatory blood pressure when ...

The FDA has approved aprocitentan (Tryvio), making it the first endothelin receptor antagonist for the treatment of high blood pressure (BP), Idorsia Pharmaceuticals announced on Wednesday. The ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Aprocitentan, a dual endothelin antagonist, was superior to placebo for BP lowering and was well ...

The study found no significant differences between the groups in terms of disease progression, morbidity or mortality, or all-cause death. Macitentan demonstrated superiority over other endothelin ...

The US Food and Drug Administration has approved aprocitentan (Tryvio) for the treatment of high blood pressure, according to an announcement today from Idorsia Pharmaceuticals, the drug’s ...

Please provide your email address to receive an email when new articles are posted on . PER-001 (Perfuse Therapeutics), an endothelin antagonist, was delivered at low and high doses and compared with ...

MONTREAL, CN (September 10, 2009) − One of the most intriguing developments in recent medical science is the discovery of the human chemical endothelin (ET). Since its detection in 1988, over 22,000 ...

IgA Nephropathy (IgAN) is a chronic autoimmune disease that affects the kidneys and leads to end-stage kidney disease. Current treatments for IgAN are limited in their effectiveness. Sparsentan, ...

Vol. 18, Supplement 1: Research from the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, and Charles R. Drew University of Medicine and Science 2007 ...